Healthcare Sector Analytics
Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices
Drug and medical device approval pathways by country
How new drugs, biologics, biosimilars, generics, over-the-counter medicines, vaccines, cell and gene therapies, combination products, medical devices, diagnostics and medical software get approved: the steps, requirements, official time targets, fees and reliance routes of each pathway.
Testing requirements and standards
Every route page has a section on technical and testing requirements: biocompatibility, bench testing, electrical safety, software, sterilization, shelf life, stability and more, with local testing rules and a comparison with the United States and the European Union. See the standards recognized by each market.
Not legal or regulatory advice. Check the current official rules before you act. Pathway pages show the date each route was last verified. Time targets are official targets, not actual review times. Parts of the approvals data are official open data reused under open licences. Data sources.
About Regulatory Pathways
How Medicines and Medical Devices Get Approved, Country by Country
The route a medicine or a medical device takes to reach a market: who reviews it, the steps, the official time targets, the fees and the reliance routes that let one regulator lean on another.
Frequently asked questions
What is a regulatory pathway?
A regulatory pathway is the legal route a medicine or medical device takes to be allowed on a market: who reviews it, what data must be filed, the steps and official time targets, and the fees. Most markets have several routes, for example a full application for a new medicine, a shorter route for generics, faster programs for serious diseases and reliance routes that use another regulator's approval.
How are routes compared across countries?
Every local route is mapped to a shared list of 28 pathway types, such as full application for a new active substance, generic, biosimilar, conditional approval, priority review, reliance, premarket notification and conformity assessment for devices. Routes of the same type appear side by side on the comparison pages.
Are the time targets actual review times?
No. Time targets come from laws, regulations and published performance goals. Actual review times are shown separately, only for markets whose official approvals data gives both the start date and the decision date.
How many markets and approval routes are covered?
20 markets have pathway pages, with 600 reviewed approval routes and programs in total. Each route is mapped to one of 28 shared pathway types so that markets can be compared.
How current is the content?
Each pathway shows the date it was last checked against the official rules; the most recent check was on October 5, 2026. Official guidance and law pages are monitored for changes, and changed pages are reviewed again.
How we calculate the regulatory pathways data
What the data is
Approval routes, steps, official time targets, fees and reliance routes for medicines and medical devices in the largest markets, plus approvals from official regulator data.
How often it updates
Approvals daily to monthly. Each pathway is checked against the regulator’s official documents at least every 12 months; the page shows the date it was last checked.
How the numbers are calculated
Time targets and fees are the official figures of each regulator, in its own currency unless a conversion is shown. Comparisons put the same steps of two markets side by side.
Limits
Official targets are not the time an actual review takes, and fees and rules change; always check the regulator’s current documents before a filing.